Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | March 2011 |
| Contact: | V Mononen |
| Phone: | +358 10 4261 |
Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of
ODM-201 in patients with castrate resistant prostate cancer.
Inclusion Criteria:
- Written informed consent
- Histologically confirmed adenocarcinoma of prostate
- Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral
orchiectomy
- Progressive metastatic disease
- Adequate bone marrow, hepatic, and renal function
Exclusion Criteria:
- Known metastases in the brain
- History of other malignancy within the previous 5 years
- Known gastrointestinal disease or procedure that affects the absorption
- Not able to swallow the study drug
We found this trial at
6
sites
823 82nd Parkway, Suite B
Myrtle Beach, South Carolina 29572
Myrtle Beach, South Carolina 29572
(843) 449-1010 ext.268
Carolina Urologic Research Center Carolina Urologic Research Center (CURC) has been recognized both nationally and...
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials